Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonists (RAs) are a class of drugs used in type 2 diabetes management. This evidence concerns the gene GIP and type 2 diabetes mellitus.